Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1Myeloid 1

Conditions

Myelodysplastic Syndromes 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Leukemia, Prolymphocytic, T-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Sarcoma, Synovial 1Sarcoma 1Primary Myelofibrosis 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Liposarcoma, Myxoid 1Leukemia, Plasma Cell 1Leukemia 1Leiomyosarcoma 1Hodgkin Disease 1Histiocytoma, Malignant Fibrous 1Hematologic Diseases 1Gastrointestinal Neoplasms 1Chondrosarcoma 1Breast Neoplasms 1

Interventions

fludarabine phosphate 6Whole-Body Irradiation 5Mycophenolic Acid 5fludarabine 4Peripheral Blood Stem Cell Transplantation 4Cyclosporins 4Cyclosporine 4Cyclophosphamide 4ruxolitinib 3Cytarabine 3venetoclax 2itacitinib 2duvelisib 2carmustine, poliferprosan 20 drug combination 2Stem Cell Transplantation 2Sirolimus 2Melphalan 2Etoposide 2Carmustine 2Alemtuzumab 2thymoglobulin 1romidepsin 1nelarabine 1letermovir 1Tacrolimus 1Mitoxantrone 1INCB039110 1Hematopoietic Stem Cell Transplantation 1Everolimus 1Depsipeptides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Leukemia, Prolymphocytic, T-Cell × itacitinib × Clear all
NCT05823571 2025-09-18

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Active not recruiting
32 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Leukemia, Plasma Cell, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myelomonocytic, Chronic

NCT03989466 2024-10-10

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 1 Completed
15 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡